Zhitong Finance App News, Global Healthcare (02666) issued an announcement. In the first three quarters of 2024, the Group promoted high-quality development of the healthcare business. The overall business performance was steady, moderate and improved, and quality was improved, and various key tasks achieved positive results. For the nine months ended September 30, 2024, the Group's revenue decreased slightly by about 1.2% compared to the same period last year, and profit during the period of common equity holders increased by about 5.1% compared to the same period last year.

Furthermore, according to the quarterly adjustment results of the Hang Seng Index Series Index released by Hang Seng Index Limited on August 16, 2024 and officially entered into force on September 9, the Hang Seng Industry Classification to which the Group belongs has been adjusted from “financial industry” to “healthcare industry” and officially entered into the Hang Seng Healthcare Index. This industry classification adjustment stems from the Group's remarkable growth in the healthcare sector in recent years. It also represents Hang Seng Index Limited's recognition of Global Healthcare's development potential in the healthcare field. It will further raise Global Healthcare's attention in the capital market, thereby effectively helping listed companies carry out market value management related work and improving the development quality of listed companies controlled by central enterprises.

In terms of comprehensive medical business, the Group continues to focus on the four support goals of “comfortable environment, first-class service, excellent technology, and efficient operation” to continuously empower the development of state-owned hospitals and improve operational efficiency and efficiency. The overall operation of the Group's medical institutions was good in the first three quarters of 2024: the number of outpatient emergency patients increased by about 4.9% compared to the same period last year, and the total number of discharges increased by about 6.7% compared to the same period last year. The average number of days spent in hospital dropped to 9.8 days, the bed usage rate remained high at around 90%, and operational efficiency continued to improve.

In terms of specialty and health technology, the Group focuses on core medical resources and adheres to “two-wheel drive” of connotative development and epitaxial expansion. While improving internal quality and efficiency of services, the Group gradually builds a large health ecosystem, provides a technological engine for innovation and development, and creates new profit growth points for the company. Currently, various lines in this section have successively made new progress in terms of layout expansion, capacity building, etc., and the foundation of industrialization has been further consolidated. For the nine months ended September 30, 2024, the medical equipment full-cycle management business revenue was RMB 0.4233 billion, up about 515.1% year on year, and profit for the period was RMB 49.6 million, up about 263.8% year on year. At the end of September, the company completed separate mergers and acquisitions with the Ophthalmology Hospital Affiliated to Shandong University of Traditional Chinese Medicine and Shandong Qingniao Softcom Co., Ltd. (a company listed on the national SME share transfer system, stock code: 831718). In addition, mergers and acquisitions of other specialty medical institutions and health technology companies are also progressing smoothly.

In terms of financial business, the Group adheres to the functional position of serving the real economy and the development of the main business, promoting the integration of industry and finance, and ensuring the safe and steady development of the business. On the cost side, the Group closely follows changes in the market situation and actively uses various domestic and foreign financing instruments to effectively control overall financing costs on the premise of fully guaranteeing reasonable and abundant capital liquidity and a stable debt maturity structure. As of September 30, 2024, the Group's total interest-bearing assets continued to grow compared to mid-2024. Net interest spreads and net interest spreads increased steadily, asset quality remained good, and provision coverage remained cautious.